Sylvester Comprehensive Cancer Center

  • 20220421 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen
    RCphone +1 (305) 2437701

    IRB: 20220421

    SDG: Not Mapped
    Disease Site(s):

    Multiple Myeloma

    Sponsor: Janssen

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 3 Randomized Study Comparing Bortezomib, enalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd)

    Eligibility Criteria - NCT04923893 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-101 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20180056

    SDG: Not Mapped
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: AMC

    Enrolling Sites:

    JMH
    Sylvester
    UMH

    Title:

    AMC-101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas A Trial of the AIDS Malignancy Consortium (AMC)

    Eligibility Criteria - NCT03220022 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190675 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20190675

    SDG: Not Mapped
    Disease Site(s):

    Leukemia, Other,Myeloid and Monocytic Leukemia

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients with Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

    Eligibility Criteria - NCT04365179 *This information has been extracted from " www.clinicaltrials.gov"

  • INCB057643 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20200314

    SDG: Not Mapped
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Incyte Corporation

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

    Eligibility Criteria - NCT04279847 *This information has been extracted from " www.clinicaltrials.gov"